As part of its broader pharmaceutical strategy, the European Commission on Tuesday released a roadmap for its planned revision of the EU’s aging pharmaceutical legislation next year.
The Commission adopted its pharmaceutical strategy last November following a public consultation earlier in the year. “[The strategy] is intended to make the European pharmaceutical system patient-centered, future-proof and crisis-resistant,” the Commission writes. (RELATED: European Commission consults on roadmap to pharmaceutical reforms, Regulatory Focus 2 June 2020; EC’s new pharmaceutical strategy highlights support for innovation, R&D, Regulatory Focus 25 November 2020).
Upon adopting the strategy, the Commission also committed to revising the pharmaceutical legislation, namely Directive 2001/83/EC and Regulation (EC) No 726/2004, by the end of 2022. The Commission says the revision will address “potential weaknesses” in the legislation that have hampered innovation and competition…
